Align Technology stock steadies as record Q2 revenue meets cautious scanner outlook
Published on 08/27/2026 at 18:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Align Technology, Inc. (US0162551016) stock is trading close to $160 on August 27, 2026, after the maker of Invisalign clear aligners reported record second quarter 2026 revenue of $1.06 billion while signaling a cautious outlook for its scanner business.
The intraday quote from a major market portal shows Align Technology at $160.38 at 12:26 p.m. EDT on August 27, 2026, up 0.48% from a previous close of $159.61 and modestly above an opening price of $158.85. The same data set indicates a 52 week trading range between $122.00 and $200.44, highlighting that the current price sits well below the recent high but comfortably above the low. With an intraday market capitalization of $11.385 billion on this date and year to date performance of 2.63%, the stock is lagging the broader S&P 500 while still posting a positive return.
According to the latest quarterly overview displayed on the quote page, Align Technology delivered second quarter fiscal 2026 revenue of $1.06 billion and earnings of $108.29 million, translating into a profit margin of 10.25% for the period. In that same Q2 2026 snapshot, earnings per share came in at $2.64 versus an estimated $2.6, indicating a modest beat on consensus expectations and underlining that the core clear aligner franchise remains the primary growth engine.
Record clear aligner revenue and scanner mix pressure
The Q2 2026 commentary embedded in the market data feed notes that Align Technology achieved record revenue of $1.06 billion largely because of stronger clear aligner sales, but also stresses that a shift toward lower priced scanner models is weighing on revenue and margins. This internal mix shift within the imaging systems and CAD/CAM segment helps explain why overall profit margins, while solid, sit just above 10% rather than expanding more aggressively despite the record top line.
Trailing twelve month figures on the same page show revenue of $4.14 billion and net income attributable to common shareholders of $413.58 million, translating into diluted EPS of $5.76 and a trailing price to earnings ratio of 27.82 based on the current share price. Against this backdrop, analysts and investors are closely watching how the margin impact from the scanner portfolio interacts with continued clear aligner volume growth, especially as management has communicated cautious guidance for the third quarter due to the mix shift toward lower price points in scanners.
The profitability metrics in the fundamentals section highlight a profit margin of 9.99%, return on assets of 7.40%, and return on equity of 10.15% on a trailing basis, suggesting that the business generates respectable returns but does not currently command the kind of high teens or twenties margin profile seen at some larger medical device peers. Levered free cash flow of $584.36 million over the trailing twelve months, alongside total cash of $1.1 billion and a modest total debt to equity ratio of 2.86%, provide financial flexibility to continue investing in digital orthodontics, scanner innovation, and software platforms without relying heavily on external financing.
Analyst targets point to upside from current levels
A detailed analyst roundup article on August 27, 2026, describes Align Technology as a global medical device company with a market capitalization of $11.4 billion and highlights that the stock has underperformed the broader S&P 500 Index and a leading healthcare sector ETF over the past 52 weeks. Based on this article, shares have increased nearly 12% over that period while the S&P 500 gained 18.7%, and they are up 1.8% on a year to date basis compared with a 12.1% return for the index. The analyst sentiment overview explains that stagnating North American clear aligner demand, intensifying competition, scanner weakness, valuation concerns, and regulatory scrutiny have weighed on the stock.
Within that same analysis, consensus forecasts for the fiscal year ending December 2026 call for adjusted earnings per share of $9.38, representing 10.9% year over year growth. The article notes that the stock is covered by 16 analysts with a consensus rating described as a "Moderate Buy", consisting of 10 strong buy ratings, five holds, and one moderate sell. It also cites a mean price target of $207.07, which implies a 30.1% premium to the current price around $160, and a high target of $240 suggesting potential upside above 50% if the company executes well and sentiment improves.
Additional analyst data visible on the quote platform corroborate that the average one year target estimate stands near $208.60, with recent actions including an initiated outperform rating and a price target around $209 from a major brokerage on July 9, 2026. These figures collectively point to a cluster of targets in the $188 to $240 range, framing the current stock price of $160.38 as meaningfully below the center of analyst expectations. For investors, the key interpreted takeaway is that the market is discounting near term scanner and demand issues, while the sell side remains constructive on longer term growth in clear aligners and digital orthodontic workflows.
Valuation, performance, and peer comparison
On valuation measures, the quote page shows a trailing P/E ratio of 27.82, reflecting the relationship between the $160.38 share price and trailing diluted EPS of $5.76, while the price to sales ratio based on $4.14 billion of trailing revenue positions Align Technology at a premium to some traditional medical equipment names but in line with higher growth specialty device firms. The enterprise value to revenue and enterprise value to EBITDA metrics in the same dataset support the view that the stock is priced for continued double digit earnings growth but not for aggressive hypergrowth.
Performance data as of August 26, 2026, reveal that Align Technology’s year to date total return of 2.63% trails the S&P 500’s 12.01% gain, and its one year return of 13.03% falls behind the index’s 18.58%. Comparatively, an analyst overview article emphasizes that the company has also underperformed a prominent healthcare sector ETF that delivered 25.8% over the past 52 weeks. This quantified comparison underscores that, despite a recovery from the 52 week low of $122.00, Align Technology shares have not kept pace with either broad market benchmarks or sector peers, reinforcing the narrative that investors are cautious on demand trends and regulatory risks.
Peer tables on the quote page list other medical instruments and supplies companies such as Intuitive Surgical, ResMed, Becton Dickinson, and The Cooper Companies, each with significantly larger market capitalizations and different growth and margin profiles. While this peer group comparison is not a direct valuation model, it situates Align Technology as a mid cap player in a sector dominated by larger names, where its differentiated clear aligner and digital orthodontics portfolio must justify premium multiples through sustained volume growth and expanding digital ecosystems.
Invisalign and the digital orthodontics platform
Align Technology’s business overview identifies its flagship Invisalign clear aligners and Vivera retainers alongside the iTero intraoral scanner portfolio and exocad CAD/CAM software as the core of its integrated digital treatment platform. The clear aligner segment includes comprehensive packages tailored to adults and teens with malocclusion, as well as specialized solutions like Invisalign First Phase I and Phase 2 for patients between six and ten years old with mixed dentition. Additional product variants such as Invisalign express, Invisalign lite, and Invisalign moderate expand the range of treatment options for different case complexities.
The company’s imaging and CAD/CAM segment offers the iTero scanner as a single hardware platform for both restorative and orthodontic procedures, complemented by software solutions for digital records, orthodontic diagnosis, restorative planning, and chair side tools such as the Invisalign outcome simulator and progress assessment. Features like the Align Oral Health Suite and iTero TimeLapse technology enable practitioners to compare historic 3D scans with current scans to visualize changes over time. Subscription software, disposables, scanner rentals, and pay per scan arrangements round out the segment, creating recurring revenue streams that support the broader ecosystem.
Recent Q2 2026 materials summarized on the quote page highlight that more than half of Invisalign cases are submitted via digital scans, and that iTero scanners account for a large portion of those digital impressions. However, the same commentary warns that the mix shift toward lower priced scanner models is pressuring revenue growth in the imaging segment, which matters because scanner sales historically contributed to both top line expansion and margin leverage by distributing fixed development costs over higher unit volumes.
Guidance, growth drivers, and risk factors
The Q2 2026 earnings trends table indicates that Align Technology slightly exceeded consensus EPS expectations for the quarter, but the accompanying narrative mentions cautious guidance for Q3 stemming from scanner mix and competitive dynamics. Analysts interviewed in the sentiment article describe stagnating North American clear aligner demand and intensifying competition as key headwinds, particularly as alternative clear aligner providers pursue aggressive pricing and marketing strategies in both dentist and direct to consumer channels.
Valuation concerns also appear in the analyst commentary, as the stock’s premium multiples relative to slower growing medical device names may be difficult to sustain if revenue growth moderates or if margin expansion is constrained by product mix. The analyst overview further references EU antitrust scrutiny as a factor adding uncertainty, although no detailed figures are given for potential regulatory outcomes. These elements combine to explain why the share price trades far below the $200.44 52 week high even knowing that Q2 2026 revenue reached a record $1.06 billion.
On the positive side, long term growth drivers include expanding global adoption of clear aligners as an alternative to traditional braces, increasing digitalization of orthodontic workflows, and broader penetration of scanners and CAD/CAM software in restorative dentistry. The trailing twelve month revenue of $4.14 billion and net income of $413.58 million show that Align Technology has already scaled to a sizeable global footprint, and the projected 10.9% growth in adjusted EPS to $9.38 for fiscal 2026 suggests expectations of continued profitable expansion.
Representative product: Invisalign clear aligners
Within Align Technology’s portfolio, Invisalign clear aligners stand out as the representative product for both revenue contribution and brand recognition. The quote page’s research summary notes that Invisalign has treated over 14 million patients since launch and can address roughly 90% of malocclusion cases, with more than 230,000 dentists and orthodontists trained to use the system. In 2022 alone, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for that year, underscoring its status as a major force in modern orthodontics.
Invisalign’s value proposition lies in its removable, nearly transparent aligner trays that offer an aesthetic alternative to fixed metal braces while allowing for digital planning and precise movement sequencing. Treatment plans are created from digital scans or impressions, processed through Align Technology’s software to generate staged aligner sets that gradually move teeth into target positions. For younger patients, specialized products like Invisalign First Phase I and Phase 2 are designed to handle mixed dentition and growth considerations, while adult offerings range from comprehensive packages to shorter duration products like Invisalign express for milder cases.
The integration of Invisalign with iTero scanners and software applications such as the Invisalign outcome simulator strengthens the overall platform by enabling practitioners to show patients visualizations of potential treatment outcomes and progress over time. In clinical practice, these capabilities can improve case acceptance rates and patient engagement, supporting the revenue growth observed in Q2 2026 and the ongoing expansion of clear aligner volumes. Looking ahead, continued innovation in aligner materials, software algorithms, and adjunctive tools may be required to maintain market share in a competitive landscape that includes both established orthodontic device manufacturers and emerging digital orthodontic startups.
Align Technology stock price context and investor view
Align Technology stock, listed on Nasdaq under the ticker ALGN, is quoted at $160.38 as of 12:26 p.m. EDT on August 27, 2026, with a day’s range between $158.62 and $161.66 and volume of 264,701 shares versus average volume of 996,530. The 52 week range from $122.00 to $200.44 places the current price in the lower half of its recent trading corridor, and the 2.63% year to date return compared with a double digit gain for the S&P 500 indicates that investors remain cautious despite record Q2 2026 revenue and consensus expectations for adjusted EPS growth of 10.9% this fiscal year.
For investors considering Align Technology, the key numbers to weigh are the record Q2 2026 revenue of $1.06 billion and profit margin of 10.25%, the trailing revenue of $4.14 billion and diluted EPS of $5.76 supporting a P/E ratio of 27.82, and the analyst mean price target of $207.07 which stands roughly 30% above the current share price. The stock’s position below its 52 week high but significantly above its low, along with its underperformance relative to the S&P 500 and a major healthcare ETF over the past 52 weeks, suggests that the market is balancing confidence in the long term clear aligner and digital platform story against nearer term concerns over scanner mix, competition, and regulatory risk.
Read more
More on Align Technology stock
Fact box
Company: Align Technology, Inc.
ISIN: US0162551016
Ticker: ALGN
Exchange: Nasdaq
Price (as of August 27, 2026, 12:26 p.m. EDT): $160.38 USD
Market cap: $11.385 billion (as of August 27, 2026)
Sector / Industry: Healthcare / Medical Instruments and Supplies
Index membership: S&P 500
